MDXG News and Press, MiMedx Group Inc From 04/30/24

2024-04-30 21:33:08 ET MiMedx Group, Inc. (MDXG) Q1 2024 Earnings Conference Call April 30, 2024, 04:30 PM ET Company Participants Matt Notarianni - Head of Investor Relations Joe Capper - Chief Executive Officer Doug Rice - Chief Financial Officer Conferen...

2024-04-30 16:05:22 ET More on MiMedx Group MiMedx Group, Inc. (MDXG) Q4 2023 Earnings Call Transcript MiMedx slips as FDA reaffirms position on Axiofill Seeking Alpha’s Quant Rating on MiMedx Group Historical earnings data for MiMedx Group Fin...

Net Sales of $85 Million Grew 18% Year-Over-Year for the First Quarter First Quarter GAAP Net Income was $9 Million First Quarter Adjusted EBITDA of $19 Million, or 22% of Net Sales Management to Host Conference Call Today, April&#...

LPL Financial Holdings Inc. (LPLA) is expected to report $3.77 for Q1 2024 Banco Santander Brasil SA American Depositary Shares each representing one unit (BSBR) is expected to report $0.14 for Q1 2023 EnLink Midstream LLC representing Limited Partner Interests (ENLC) is expected to repor...

2024-04-25 10:00:28 ET More on Health Care Select Sector SPDR XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance BofA watched clients retract $2B last week as the S&P dropped ...

MARIETTA, Ga., April 16, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the first quarter ended March 31, 2024 after the market close on Tuesday, April 3...

2024-03-27 09:09:56 ET More on MiMedx Group MiMedx Group, Inc. (MDXG) Q4 2023 Earnings Call Transcript MiMedx Group: Restructuring Changes Are Paying Off MiMedx announces new senior secured credit facilities, debt refinancing MiMedx gets FDA warning letter ov...

Receives Determination Letter from FDA Stating AXIOFILL Does Not Qualify for Classification as an HCT/P Under Section 361 MIMEDX Continues to Pursue All Available Options to Keep AXIOFILL on the Market Reiterates Expectations for 2024 Net Sales Percentage Growth in the Low Doubl...

2024-03-21 07:59:20 ET More on TELA Bio TELA Bio: Looks Like A Buy, But Some Pieces Missing To Make This A Strong Buy Seeking Alpha’s Quant Rating on TELA Bio Historical earnings data for TELA Bio Financial information for TELA Bio Read the f...

MARIETTA, Ga., March 20, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it has entered into an agreement with TELA Bio, Inc. to obtain exclusive rights to its manufacturing and supply agreement with Regenity ...